Sebastian Schlaweck

Hematologist/Oncologist @UniBonn @UniklinikBonn Postdoc @HeineLab Fellow @MSSOabcd

[Sebastian Schlaweck @schlaweck]

Check out our new preprint!
We unveil the role of the CCL17/CCR4 axis in aGvHD and show how CD4+ T cell contribute to intestinal aGvHD. https://t.co/3ESHKVo31h
@AnnaHeine4 @don8719 @MichelleKlesse @MSSOabcd @IMMEI_Bonn

[Sebastian Schlaweck @schlaweck]

Congrats to our brillant PhD Students! Well deserved!

[HeineLab @HeineLab]

Congrats to our 3 amazing PhD students Nils, Michelle and Gina on their poster awards @ this year's #ClusterScienceDays @ImmunoSens @UniklinikBonn Cudos to our fearless leader @AnnaHeine4 👩‍🔬🫶🧪

[HeineLab @HeineLab]

Pacritinib a novel JAK inhibitor seems to be less suppressive to DCs compared to Ruxolitinib.
In our recent study we compare both.
What do you think? Might this be a valuable therapy option for selected patients?

@annaheine4 @schlaweck

https://t.co/a7k1kG7b2N

[Sebastian Schlaweck @schlaweck]

Happy to share our latest story!
Idelalisib does not only impair T cell function but also supresses Dendritic Cells! This may contribute to the increased infection rate in patients but does it also open novel therapeutic venues??https://t.co/JB8ioO8Fg7
@HeineLab

@AnnaHeine4

[HeineLab @HeineLab]

The treatment options in Multiple Myeloma are evolving and sometimes it is hard to choose the right drug. Here we provide additional insights on the side effects of Elotuzmab and can show that it protects DCs!
https://t.co/vu0BQKezbg
@schlaweck @ImmunoSens